epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

EPI-301, Phase III. Recruiting

Non-small cell lung cancer, second line

NWT-4471 with docetaxel against docetaxel alone in previously treated non-small cell lung cancer. Sponsor: Northwind Therapeutics (fictional), Oncology.

Which sites are ahead, on target or behind their expectation, where each loses its patients, and what might help.

Sites at a glance

Data to September 30th 2026. Sponsor: Northwind Therapeutics (fictional). Study-level KPIs and QTLs have their own tabs: KPIs and QTLs.

Patients randomised

171 of 400

43% of the target

Sites open

159 of 159

Every planned site is open

Patients screened

322

Up: +90 in the last three months

Sites behind their expectation

5 of 10 judged

Behind 3 ahead, 2 on target, 149 too early to judge

See sites behind

Agreed, of patients approached

57%

55% in published cancer trials

Randomised, of patients screened

53%

The plan assumed 60%

Are enough patients being screened?

Over the last three months the study screened about 30 patients a month; since it began, 53% of patients screened have been randomised. Randomising the remaining 229 by the planned last patient in January 2028 takes about 29 screens a month, 1.0 times the recent pace. At the recent pace the target falls in January 2028.

Screening is keeping pace with the plan

Patients screenedCumulative, against the screens the plan implies: its expected randomisations divided by the 60% it expects to pass screening

Show data
Patients screened: planned and actual, by month
MonthPlannedActual
Jan 202500
Apr 202500
Jul 202544
Oct 20252929
Jan 20268582
Apr 2026164147
Jul 2026255232
Oct 2026349322

Sources: epiClinical synthetic screening logs; screen failure by therapeutic area from the planner parameters (D23)

How each kind of site is doing

Each site is compared with what it was expected to recruit in its months open, given its type, track record, country and the protocol. Below 75% of that is behind; above 125% is ahead.

Five out of ten sites are behind; sites of the same kind differ widely

Patients randomised as a share of those expectedEach dot a site, by profile; log scale; the shaded band is on target

Show data
Each judged site: patients randomised against expected, by profile
SiteProfileRandomisedExpectedObserved ÷ expectedStanding
301-US-36, DallasDedicated research centre02.7×0.00Behind
301-UK-15, LondonComprehensive cancer centre32.3×1.33Ahead
301-ES-11, Santiago de CompostelaRegional teaching hospital22.2×0.92On target
301-ES-28, BilbaoDedicated research centre62.3×2.60Ahead
301-ES-29, BarcelonaComprehensive cancer centre12.3×0.44Behind
301-TR-01, AnkaraComprehensive cancer centre12.5×0.40Behind
301-TR-04, BursaRegional teaching hospital52.4×2.09Ahead
301-IN-06, VelloreDedicated research centre12.3×0.43Behind
301-IN-08, NagpurDedicated research centre23.6×0.55Behind
301-IN-11, HyderabadDedicated research centre22.4×0.83On target

Source: epiClinical synthetic sites. Left out: 149 sites where fewer than two patients were expected so far, too few to judge.

Sites behind, and what might help

Largest shortfall first. Each site's screening log is split into three stages against the study as a whole; the stage marked is where it loses most. A likely cause needs both a leak at its stage and the fact that goes with it, so it was found for four of five sites. Suggestions wait for a person to accept or dismiss them. Nothing changes the plan on its own, and in a real system each decision is audit-logged.

Behind

301-US-36, Dallas

Dedicated research centre, United States · 0 randomised against 2.7 expected in 17 months open
  1. Approached×0.222 patients, 9 expected
  2. Agreed–2 patients approached, too few to judge
  3. Passed screening–1 patient screened, too few to judge
Likely cause
Competing trials take the same patients. The site approaches fewer patients than a site like it should, and runs other trials for the same patients. Investigators offer each patient one trial, so this study gets only a share of them. Known about this site: two or more competing trials open at the site.
Also known
Does not check records against the criteria before inviting patients.
  1. Agree with the investigator how patients are offered the competing trials.

    An operational step with no outcome evidence; it makes the site's choice visible.

  2. Central campaigns, recruitment vendors and referral networks. Referral routes from centres without the competing trials widen the pool.

    D Evidence grade D. No quantitative evidence found in peer-reviewed comparative studies within this review. Context: in cancer care, no trial was available at the patient's centre for 55.6% of patients, which referral networks aim to address.

  3. Add sites or countries. If several sites share the problem, add sites where competition is lower.

    D Evidence grade D. No quantitative evidence on adding sites as a rescue. Diminishing returns follow from activation lag and site variability rather than from a measured effect. Context: median 0.95 participants per centre per month (IQR 0.42 to 2.60) in NIHR trials.

Behind

301-IN-08, Nagpur

Dedicated research centre, India · 2 randomised against 3.6 expected in 15 months open
  1. Approached×1.0813 patients, 12 expected
  2. Agreed×0.6838%, study 57%
  3. Passed screening–5 patients screened, too few to judge
Likely cause
No stage stands out from the study; the shortfall may be chance or a cause not recorded here.
Also known
Does not check records against the criteria before inviting patients; Relies on referrals, with no formal referral network.
  1. Screening-log review to find the leaking funnel stage. No known cause fits, so start by finding which stage loses patients and why.

    C Evidence grade C. No quantitative evidence that logs raise recruitment. In one oncology trial, logs showed 91% of eligible patients approached but 40% agreeing, pointing at the consent conversation; logs were incomplete (47% returned; 28% of enrolled patients missing).

Behind

301-TR-01, Ankara

Comprehensive cancer centre, Turkey · 1 randomised against 2.5 expected in 14 months open
  1. Approached×0.484 patients, 8 expected
  2. Agreed–4 patients approached, too few to judge
  3. Passed screening–3 patients screened, too few to judge
Likely cause
Competing trials take the same patients. The site approaches fewer patients than a site like it should, and runs other trials for the same patients. Investigators offer each patient one trial, so this study gets only a share of them. Known about this site: two or more competing trials open at the site.
  1. Agree with the investigator how patients are offered the competing trials.

    An operational step with no outcome evidence; it makes the site's choice visible.

  2. Central campaigns, recruitment vendors and referral networks. Referral routes from centres without the competing trials widen the pool.

    D Evidence grade D. No quantitative evidence found in peer-reviewed comparative studies within this review. Context: in cancer care, no trial was available at the patient's centre for 55.6% of patients, which referral networks aim to address.

  3. Add sites or countries. If several sites share the problem, add sites where competition is lower.

    D Evidence grade D. No quantitative evidence on adding sites as a rescue. Diminishing returns follow from activation lag and site variability rather than from a measured effect. Context: median 0.95 participants per centre per month (IQR 0.42 to 2.60) in NIHR trials.

Behind

301-IN-06, Vellore

Dedicated research centre, India · 1 randomised against 2.3 expected in 14 months open
  1. Approached×0.393 patients, 8 expected
  2. Agreed–3 patients approached, too few to judge
  3. Passed screening–2 patients screened, too few to judge
Likely cause
Too few patients referred. The site approaches fewer patients than a site like it should, and has no clinic of its own for these patients. It depends on other doctors remembering to refer. Known about this site: relies on referrals, with no formal referral network.
Also known
Two in five patients or more travel over an hour.
  1. Central campaigns, recruitment vendors and referral networks. A formal referral network or a central campaign brings patients the site cannot reach itself.

    D Evidence grade D. No quantitative evidence found in peer-reviewed comparative studies within this review. Context: in cancer care, no trial was available at the patient's centre for 55.6% of patients, which referral networks aim to address.

  2. Opt-out contact for potential participants. Where the site holds a patient database, opt-out contact reaches more of it; needs ethics and data-protection approval.

    C Evidence grade C. RR 1.39 (95% CI 1.06 to 1.84), but from a single study of 152 people; not among the high-certainty findings of the 2018 update.

Behind

301-ES-29, Barcelona

Comprehensive cancer centre, Spain · 1 randomised against 2.3 expected in 13 months open
  1. Approached×0.262 patients, 8 expected
  2. Agreed–2 patients approached, too few to judge
  3. Passed screening–2 patients screened, too few to judge
Likely cause
Competing trials take the same patients. The site approaches fewer patients than a site like it should, and runs other trials for the same patients. Investigators offer each patient one trial, so this study gets only a share of them. Known about this site: two or more competing trials open at the site.
  1. Agree with the investigator how patients are offered the competing trials.

    An operational step with no outcome evidence; it makes the site's choice visible.

  2. Central campaigns, recruitment vendors and referral networks. Referral routes from centres without the competing trials widen the pool.

    D Evidence grade D. No quantitative evidence found in peer-reviewed comparative studies within this review. Context: in cancer care, no trial was available at the patient's centre for 55.6% of patients, which referral networks aim to address.

  3. Add sites or countries. If several sites share the problem, add sites where competition is lower.

    D Evidence grade D. No quantitative evidence on adding sites as a rescue. Diminishing returns follow from activation lag and site variability rather than from a measured effect. Context: median 0.95 participants per centre per month (IQR 0.42 to 2.60) in NIHR trials.

Zero out of ten judged sites are outside the range the planner's model allows by chance. Site rates vary so widely (coefficient of variation 0.9) that one site's shortfall is rarely proof of a problem. Behind is a prompt to look, not a verdict.

What sites behind have in common

Share of sites with each fact, by how they are doing. A fact far more common among sites behind is worth checking at feasibility for the next study. In this synthetic data the links were built in; with real data, this table is where they would first show.

FactAheadOn targetBehind
Does not check records against the criteria before inviting patients33%50%40%
Screening scans are done at another hospital0%0%0%
Half a coordinator or less on this study33%50%0%
Two or more competing trials open at the site0%50%60%
Relies on referrals, with no formal referral network0%0%40%
Two in five patients or more travel over an hour0%50%20%

Every site

Show all 159 sites
SiteProfileMonths openExpectedRandomisedApproachedScreenedPassed screeningStanding
301-US-01, HoustonCommunity hospital12.90.50110%Too early
301-US-02, San DiegoRegional teaching hospital16.91.60320%Too early
301-US-03, CharlotteSite new to research12.60.914250%Too early
301-US-04, ChicagoSite new to research16.01.10320%Too early
301-US-05, Los AngelesComprehensive cancer centre15.41.4010–Too early
301-US-06, SeattleRegional teaching hospital13.51.336650%Too early
301-US-07, PhiladelphiaSite new to research15.71.1131100%Too early
301-US-08, NashvilleCommunity specialist practice11.50.8131100%Too early
301-US-09, AtlantaDedicated research centre11.51.928450%Too early
301-US-10, BostonComprehensive cancer centre16.91.60630%Too early
301-US-11, Salt Lake CityCommunity hospital13.31.10110%Too early
301-US-12, ClevelandRegional teaching hospital13.61.3010–Too early
301-US-13, DenverDedicated research centre14.01.7210633%Too early
301-US-14, PittsburghCommunity hospital13.01.00310%Too early
301-US-15, New YorkSite new to research14.01.2020–Too early
301-US-16, DallasRegional teaching hospital13.21.2000–Too early
301-US-17, MiamiRegional teaching hospital15.71.50220%Too early
301-US-18, BaltimoreCommunity hospital14.61.2000–Too early
301-US-19, PhoenixRegional teaching hospital11.60.5000–Too early
301-US-20, MinneapolisSite new to research14.51.027367%Too early
301-US-21, HoustonSite new to research12.10.6343100%Too early
301-US-22, San DiegoDedicated research centre13.81.60410%Too early
301-US-23, CharlotteSite new to research11.61.0111100%Too early
301-US-24, ChicagoCommunity specialist practice15.41.5000–Too early
301-US-25, Los AngelesDedicated research centre12.91.5411667%Too early
301-US-26, SeattleSite new to research11.81.124450%Too early
301-US-27, PhiladelphiaComprehensive cancer centre15.00.7000–Too early
301-US-28, NashvilleSite new to research14.00.813250%Too early
301-US-29, AtlantaSite new to research13.40.815250%Too early
301-US-30, BostonDedicated research centre16.00.913250%Too early
301-US-31, Salt Lake CitySite new to research11.60.8000–Too early
301-US-32, ClevelandCommunity hospital15.91.30320%Too early
301-US-33, DenverSite new to research11.41.0010–Too early
301-US-34, PittsburghDedicated research centre11.21.315250%Too early
301-US-35, New YorkSite new to research12.61.1111100%Too early
301-US-36, DallasDedicated research centre16.62.70210%Behind
301-US-37, MiamiCommunity specialist practice12.61.2020–Too early
301-US-38, BaltimoreRegional teaching hospital13.51.30110%Too early
301-US-39, PhoenixSite new to research12.90.90110%Too early
301-US-40, MinneapolisSite new to research13.81.0010–Too early
301-US-41, HoustonComprehensive cancer centre13.21.224367%Too early
301-US-42, San DiegoSite new to research11.50.80540%Too early
301-US-43, CharlotteCommunity hospital11.51.3000–Too early
301-US-44, ChicagoComprehensive cancer centre12.01.1131100%Too early
301-US-45, Los AngelesCommunity hospital14.21.6333100%Too early
301-US-46, SeattleRegional teaching hospital13.61.3111100%Too early
301-US-47, PhiladelphiaCommunity specialist practice11.60.8333100%Too early
301-US-48, NashvilleSite new to research16.40.914250%Too early
301-US-49, AtlantaRegional teaching hospital12.31.6131100%Too early
301-US-50, BostonComprehensive cancer centre13.51.30310%Too early
301-UK-01, CardiffRegional teaching hospital12.21.316333%Too early
301-UK-02, NewcastleSite new to research14.41.0242100%Too early
301-UK-03, GlasgowComprehensive cancer centre11.71.3000–Too early
301-UK-04, BirminghamComprehensive cancer centre15.51.726540%Too early
301-UK-05, LeedsCommunity hospital12.91.60210%Too early
301-UK-06, SouthamptonRegional teaching hospital12.81.9111100%Too early
301-UK-07, OxfordComprehensive cancer centre15.71.725367%Too early
301-UK-08, CambridgeSite new to research16.61.3141100%Too early
301-UK-09, LiverpoolDedicated research centre14.72.00110%Too early
301-UK-10, NottinghamCommunity hospital13.51.249580%Too early
301-UK-11, SheffieldRegional teaching hospital11.71.3131100%Too early
301-UK-12, EdinburghRegional teaching hospital11.31.215425%Too early
301-UK-13, BristolSite new to research13.61.1010–Too early
301-UK-14, ManchesterComprehensive cancer centre13.91.5353100%Too early
301-UK-15, LondonComprehensive cancer centre15.02.3343100%Ahead
301-UK-16, CardiffRegional teaching hospital11.71.8565100%Too early
301-UK-17, NewcastleSite new to research14.01.10540%Too early
301-UK-18, GlasgowComprehensive cancer centre11.21.227450%Too early
301-UK-19, BirminghamComprehensive cancer centre11.61.7000–Too early
301-UK-20, LeedsRegional teaching hospital11.21.7353100%Too early
301-UK-21, SouthamptonRegional teaching hospital16.41.838475%Too early
301-UK-22, OxfordCommunity hospital12.31.6510683%Too early
301-UK-23, CambridgeCommunity hospital12.21.10210%Too early
301-UK-24, LiverpoolSite new to research16.01.3131100%Too early
301-UK-25, NottinghamCommunity hospital13.31.7252100%Too early
301-ES-01, ZaragozaRegional teaching hospital13.31.7222100%Too early
301-ES-02, MadridSite new to research11.71.1610875%Too early
301-ES-03, SalamancaRegional teaching hospital10.61.3262100%Too early
301-ES-04, ValenciaComprehensive cancer centre10.81.915250%Too early
301-ES-05, CórdobaRegional teaching hospital7.40.928367%Too early
301-ES-06, OviedoCommunity specialist practice12.01.6010–Too early
301-ES-07, GranadaSite new to research12.81.20220%Too early
301-ES-08, SevilleComprehensive cancer centre11.61.50110%Too early
301-ES-09, PamplonaRegional teaching hospital10.21.8510683%Too early
301-ES-10, MurciaRegional teaching hospital12.81.6010–Too early
301-ES-11, Santiago de CompostelaRegional teaching hospital12.42.224450%On target
301-ES-12, MálagaRegional teaching hospital13.11.7565100%Too early
301-ES-13, BilbaoDedicated research centre8.60.7000–Too early
301-ES-14, BarcelonaComprehensive cancer centre11.81.5111100%Too early
301-ES-15, AlicanteRegional teaching hospital11.01.427540%Too early
301-ES-16, ZaragozaRegional teaching hospital11.61.513250%Too early
301-ES-17, MadridSite new to research12.41.00310%Too early
301-ES-18, SalamancaRegional teaching hospital11.91.526450%Too early
301-ES-19, ValenciaSite new to research10.91.00210%Too early
301-ES-20, CórdobaRegional teaching hospital9.81.20210%Too early
301-ES-21, OviedoRegional teaching hospital11.22.0252100%Too early
301-ES-22, GranadaSite new to research12.01.1010–Too early
301-ES-23, SevilleCommunity hospital10.81.616250%Too early
301-ES-24, PamplonaRegional teaching hospital13.30.815250%Too early
301-ES-25, MurciaCommunity hospital10.51.1161100%Too early
301-ES-26, Santiago de CompostelaRegional teaching hospital8.51.5242100%Too early
301-ES-27, MálagaSite new to research9.50.9121100%Too early
301-ES-28, BilbaoDedicated research centre10.52.36171060%Ahead
301-ES-29, BarcelonaComprehensive cancer centre13.02.312250%Behind
301-ES-30, AlicanteRegional teaching hospital10.81.424367%Too early
301-ES-31, ZaragozaRegional teaching hospital13.11.7210729%Too early
301-ES-32, MadridComprehensive cancer centre13.41.713250%Too early
301-ES-33, SalamancaRegional teaching hospital12.21.515333%Too early
301-ES-34, ValenciaComprehensive cancer centre7.50.90420%Too early
301-ES-35, CórdobaRegional teaching hospital7.70.5000–Too early
301-PL-01, WarsawSite new to research8.11.1000–Too early
301-PL-02, RzeszówCommunity specialist practice8.21.5000–Too early
301-PL-03, OlsztynSite new to research6.21.035475%Too early
301-PL-04, BydgoszczSite new to research4.90.814333%Too early
301-PL-05, ZamośćDedicated research centre6.81.5000–Too early
301-PL-06, LublinCommunity hospital5.90.9131100%Too early
301-PL-07, SzczecinRegional teaching hospital7.41.30110%Too early
301-PL-08, KatowiceDedicated research centre8.20.923367%Too early
301-PL-09, KrakówComprehensive cancer centre8.00.70110%Too early
301-PL-10, GdańskComprehensive cancer centre4.50.4000–Too early
301-PL-11, BiałystokDedicated research centre5.91.828540%Too early
301-PL-12, WrocławDedicated research centre6.40.7000–Too early
301-PL-13, ŁódźDedicated research centre4.41.40310%Too early
301-PL-14, PoznańCommunity specialist practice9.51.819425%Too early
301-PL-15, WarsawComprehensive cancer centre4.40.815250%Too early
301-PL-16, RzeszówRegional teaching hospital5.51.015333%Too early
301-PL-17, OlsztynRegional teaching hospital7.91.4111100%Too early
301-PL-18, BydgoszczCommunity specialist practice6.40.8030–Too early
301-PL-19, ZamośćCommunity hospital3.90.6000–Too early
301-PL-20, LublinDedicated research centre7.10.8000–Too early
301-PL-21, SzczecinCommunity hospital4.80.4000–Too early
301-PL-22, KatowiceRegional teaching hospital9.50.8222100%Too early
301-PL-23, KrakówSite new to research5.60.70410%Too early
301-PL-24, GdańskDedicated research centre6.91.50730%Too early
301-PL-25, BiałystokSite new to research7.81.30110%Too early
301-TR-01, AnkaraComprehensive cancer centre14.22.514333%Behind
301-TR-02, AntakyaSite new to research11.31.10310%Too early
301-TR-03, DiyarbakırSite new to research11.81.10520%Too early
301-TR-04, BursaRegional teaching hospital13.62.459683%Ahead
301-TR-05, MalatyaRegional teaching hospital12.11.5010–Too early
301-TR-06, AdanaCommunity hospital14.11.50520%Too early
301-TR-07, İzmirCommunity specialist practice13.01.7211825%Too early
301-TR-08, IstanbulComprehensive cancer centre14.31.814333%Too early
301-TR-09, AntalyaSite new to research14.21.3222100%Too early
301-TR-10, KayseriRegional teaching hospital10.11.8131100%Too early
301-TR-11, GaziantepRegional teaching hospital9.11.1000–Too early
301-TR-12, KonyaCommunity hospital11.81.315250%Too early
301-IN-01, MumbaiCommunity specialist practice13.31.40220%Too early
301-IN-02, ChandigarhRegional teaching hospital11.11.50610%Too early
301-IN-03, DelhiComprehensive cancer centre11.61.60220%Too early
301-IN-04, KochiRegional teaching hospital9.10.6010–Too early
301-IN-05, JaipurRegional teaching hospital12.31.7121100%Too early
301-IN-06, VelloreDedicated research centre13.52.313250%Behind
301-IN-07, ChennaiComprehensive cancer centre11.81.6111100%Too early
301-IN-08, NagpurDedicated research centre15.03.6213540%Behind
301-IN-09, PuneRegional teaching hospital13.71.9252100%Too early
301-IN-10, AhmedabadRegional teaching hospital13.71.9000–Too early
301-IN-11, HyderabadDedicated research centre14.02.427450%On target
301-IN-12, LucknowCommunity specialist practice14.71.5121100%Too early

Rules behind this page

  • A site that has recruited below this share of its expected count is behind: 75%. epiClinical assumption, between the enrolment flag (0.8) and the point NCI trials rarely recovered from (0.6); about half of sites fall short of plan in practice (11% enrol nobody, 37% under-enrol; Tufts, register S-01).
  • A site that has recruited above this share of its expected count is ahead: 125%. epiClinical assumption, set symmetrically to the behind line on a ratio scale (1 ÷ 0.8).
  • Patients a site must have been expected to recruit before it is judged: 2. epiClinical assumption: below this, a site's count says more about chance than about the site.
  • Patients offered a trial who agree to take part: 55%. 55.0% of patients offered a cancer treatment trial agreed, across 35 studies (Unger 2021, JNCI, https://doi.org/10.1093/jnci/djaa155).
  • Patients needed at a funnel stage before a site's rate there is compared with the study's: 8. epiClinical assumption: with fewer, a single patient moves the rate by more than ten points.
  • A site's rate at a funnel stage is out of line when so poor a rate would happen by chance less often than this: 0.1. epiClinical assumption: a loose screen, because it prompts a look at the screening log rather than a judgement.
  • Patients fail screening: Screen failure is high and varies widely by therapeutic area (register PM-05); restrictive criteria are the commonest design barrier (PB-02, PD-01).
  • Patients wait too long for scans: epiClinical assumption from CRA practice; procedures per protocol rose 40.6% since 2010, which weighs on sites without services on site (register S-24).
  • Too little coordinator time: Coordinator turnover of 10 to 37% a year, rising to 35 to 61% in 2022; 45% of sites say capacity limits new studies (register S-09, S-11).
  • Competing trials take the same patients: Competing trials for the same patients reduce enrolment where the eligible pool is scarce (register EB-02, S-21).
  • Too few patients referred: Research-focused sites recruit about 41% better, but depend on referral routes (register S-07); referral networks lack outcome evidence (action A14).
  • Patients decline because of the journey: Procedural and visit burden lowers enrolment and retention (register PD-03); decentralised elements help mainly where travel is the barrier (PD-20).